Copying articles to share with others is a breach of our terms and conditions and copywriter policy. Please use the sharing options on the left side of the article. Devex Pro subscribers may share up to 10 articles per month using the Pro share tool ( ).
Inside Development
Health supply chains
Q&A: How Chemonics went from corrective action to commercial solutions
By Michael Igoe // 09 October 2019
Devex speaks with Jamey Butcher, incoming CEO of Chemonics International, about how the USAID contractor responded to early challenges with the $9.5 billion global health supply chain project.
This story is forDevex Pro subscribers
Unlock this story now with a 15-day free trial of Devex Pro.
With a Devex Pro subscription you'll get access to deeper analysis and exclusive insights from our reporters and analysts.
Start your free trialGet a group subscription
Should your team be reading this?
Contact us about a group subscription to Pro.
Michael Igoe@AlterIgoe
Michael Igoe is a Senior Reporter with Devex, based in Washington, D.C. He covers U.S. foreign aid, global health, climate change, and development finance. Prior to joining Devex, Michael researched water management and climate change adaptation in post-Soviet Central Asia, where he also wrote for EurasiaNet. Michael earned his bachelor's degree from Bowdoin College, where he majored in Russian, and his master's degree from the University of Montana, where he studied international conservation and development.
Community Health Coordinator
Programme Officer: Head Procurement and Supply Chain Management
Freshwater Health Index Coordinator
Global health supply chain
Chemonics expects health supply chain project extension through 2023
Q&A: How USAID is responding to Iraq's violent crackdown
Q&A: Employee engagement is key to progress on diversity and inclusion
Q&A: The ups and downs of WHO's Health Emergencies Programme